I am not sure when they previously disclosed that the Company had received formal information requests (i.e., subpoenas) from the SEC regarding the planned publication of interim trial data.
I looked back at recent 10Qs and 8Ks (dating back to ASCO 2017) and didn't find that disclosed anywhere else but in today's 10K.
Anyone else remember seeing that disclosure previously?
I have a hard time believing it would have escaped the notice of this entire board if in fact it had been disclosed previously.
"As previously reported, the Company has received a number formal information requests (subpoenas) from the SEC regarding several broad topics that have been previously disclosed, including the Company’s membership on Nasdaq and delisting, related party matters, the Company’s programs, internal controls, the Company’s Special Litigation Committee, disclosures and the planned publication of interim clinical trial data. Testimony of certain officers and third parties has been taken as well. The Company is cooperating with the SEC investigation and is hopeful that it is reaching its final stages."
I'll give you that it sounds serious, and yet is completely juxtaposed by LP, Cognate and others achieving a confident share grab during this time under the proverbial microscope. It's difficult to reconcile one way or the other. Another wait and see. What does it mean?
looks like great progress at the investigation front. SEC subpoenas usually can be complied with explanations and testimonies producing facts and submitting affidavits cooperating when you have nothing to hide. LP et al are all lawyers and they know how to be responsive better than naysayers here. Looks like Coffer Black's show is about to begin starting from SEC investigation that might be bad for those who have something to hide. sorry for the wolf pack.
As previously reported, on December 13, 2016, the Company received a formal information request (subpoena) from the SEC regarding several broad topics that have been previously disclosed, including the Company’s membership on Nasdaq and delisting, related party matters, internal controls and the Company’s Special Litigation Committee. The period covered is January 1, 2013 to the present. The investigation is ongoing and the Company is cooperating fully.
2017 10-K As previously reported, the Company has received a number formal information requests (subpoenas) from the SEC regarding several broad topics that have been previously disclosed, including the Company’s membership on Nasdaq and delisting, related party matters, the Company’s programs, internal controls, the Company’s Special Litigation Committee, disclosuresand the plannedpublication of interim clinical trial data. Testimony of certain officers and third parties has been taken as well. The Company is cooperating with the SEC investigation and is hopeful that it is reaching its final stages."
So really, there were three new information requests in 2017, regarding:
1. The Company's Programs. 2. Disclosures. 3. Planned Publication of Interim Data.